Antihistamines and itch — SAQ

Stem

A 28-year-old woman presents with a 3-month history of recurrent itchy wheals that appear on most days, each lesion fading without bruising. She has no angioedema, no systemic symptoms, and no clear trigger. She has been taking a standard-dose second-generation H1 antihistamine with partial relief. She is otherwise healthy, not pregnant, and works as a schoolteacher. Her examination shows scattered erythematous wheals and a positive dermatographism.^[1]

Questions

a) What is the most likely diagnosis, and how would you classify it? (2 marks)

^[1]

b) Explain the mechanism of action of H1 antihistamines and why second-generation agents are preferred over first-generation agents for this condition. (3 marks)

^{[2] [3]}

c) Outline a stepwise management plan, including the guideline ceiling before omalizumab. (3 marks)

^{[4] [6]}

d) What are the key safety considerations if she were 75 years old, or if she later became pregnant? (2 marks)

^{[7] [6]}

Model answer (must-hit points)

a) Diagnosis and classification (2 marks) ^[1]

• Chronic spontaneous urticaria — spontaneously recurring wheals, angioedema, or both, here for more than six weeks without a definite trigger — 1 mark.
• Most common in females aged 30 to 50 years; persists for more than 1 year in most patients (one or repeated episodes) — 1 mark.

b) Mechanism of H1 antihistamines and second-generation preference (3 marks)

• H1 antihistamines are inverse agonists: they combine with and stabilise the inactive receptor conformation and may down-regulate constitutive activity even in the absence of histamine (Leurs) — 1 mark. ^[2]
• CSACI: first-generation agents (diphenhydramine, hydroxyzine) cause sedation, decreased cognitive function, poor sleep, dry mouth, dizziness, and orthostatic hypotension, and have been found to result in death from accidents, overdoses, and sudden cardiac death — 1 mark. ^[3]
• Newer-generation H1-antihistamines are the recommended first-line treatment for allergic rhinitis and urticaria; first-generation agents should be used only as a last resort — 1 mark. ^[3]

c) Stepwise management plan (3 marks)

• Continue a second-generation H1 antihistamine at standard dose; partial or complete response (greater than 50 percent symptom reduction) occurs in approximately 40 percent — 1 mark. ^[1]
• If inadequate, step-up to four-fold the approved dose (Zuberbier/international pathway; Torres-Betato: up-dosing to four times can enhance control without compromising tolerability; Wang: bilastine up to 80 mg once daily) — 1 mark. ^[4][6][8]
• If still refractory, add omalizumab (2022 guideline second-line). Saini: a single subcutaneous 300 mg or 600 mg dose improved UAS7; 75 mg did not. At least 30 percent respond insufficiently. Ciclosporin is off-label (approximately 54 to 73 percent improve) — 1 mark. ^[1][5]

d) Elderly and pregnancy (2 marks)

• Older adult: antihistamines are among the most common anticholinergic classes in community-dwelling older adults (Pelen); CSACI — first-generation last resort. Prefer a newer-generation agent. Wang: bilastine does not require renal-impairment dose adjustment — 1 mark. ^[7][3][8]
• Pregnancy: Torres-Betato — generally safe in paediatric, elderly, and organ-impaired patients with appropriate caution during pregnancy and lactation. Ranked “safest in pregnancy” agent lists are not in the fetched abstracts — 1 mark. ^[6]

Common errors

• Stopping at standard dose and calling the patient refractory.
• Switching to a first-generation agent for chronic daytime CSU.
• Quoting milligram cetirizine 40 mg, omalizumab 150–300 mg every 4 weeks, or ciclosporin 3–5 mg/kg when those recipes are not in the cited abstracts.
• Claiming a named agent is the safest in pregnancy without a fetched ranking.

^{[1] [3] [4] [6]}

References8ShowHide

1. [1]Kolkhir P, Bonnekoh H, Metz M, et al. Chronic Spontaneous Urticaria: A Review JAMA, 2024.PMID 39325444
2. [2]Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects Clin Exp Allergy, 2002.PMID 11972592
3. [3]Fein MN, Fischer DA, O'Keefe AW, et al. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria Allergy Asthma Clin Immunol, 2019.PMID 31582993
4. [4]Zuberbier T, Ensina LF, Giménez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment Lancet, 2024.PMID 39004090
5. [5]Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria J Allergy Clin Immunol, 2011.PMID 21762974
6. [6]Torres-Betato F, Arnau AMG, Spertino J. Efficacy, safety, and clinical use of second-generation antihistamines for chronic spontaneous urticaria: a comprehensive review Eur J Dermatol, 2026.PMID 42507398
7. [7]Pelen K, Hagenimana WB, Baroud ML, et al. Prevalence and factors associated with anticholinergic medication use in community-dwelling older adults: a systematic review Int J Clin Pharm, 2025.PMID 41066035
8. [8]Wang XY, Lim-Jurado M, Prepageran N, et al. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine Ther Clin Risk Manag, 2016.PMID 27110120